<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04619082</url>
  </required_header>
  <id_info>
    <org_study_id>IRB2020091</org_study_id>
    <nct_id>NCT04619082</nct_id>
  </id_info>
  <brief_title>TAF to Prevent HBV Reactivation in Cancer Patients</brief_title>
  <official_title>The Efficacy and Safety of TAF as a Prophylactic Antiviral Agent for HBsAg-positive Cancer Patients Receiving Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chiayi Christian Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>St. Martin De Porress Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Dalin Tzu Chi General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Taiwan University Hospital, Yun-Lin Branch</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chi Mei Medical Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Chiayi Christian Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Tenofovir alafenamide (TAF) has been approved to prevent HBV reactivation for HBsAg-positive&#xD;
      cancer patients receiving chemotherapy. However, the real-world effectiveness and safety of&#xD;
      TAF for cancer patients was lacing. Therefore, we conduct a prospective single arm study to&#xD;
      evaluate the efficacy and safety of TAF as a prophylactic antiviral agent for HBsAg-positive&#xD;
      cancer patients receiving chemotherapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This prospective single arm study would be conducted in Taiwan. Patients who fulfill the&#xD;
      inclusion criteria, will receive TAF before the initiation of systemic chemotherapy. Based on&#xD;
      the guidance of NHI in Taiwan, prophylactic anti-viral agent should be prescribed within 7&#xD;
      days before chemotherapy and would be discontinued at 6 months after cessation of&#xD;
      chemotherapy. The duration of TAF prophylaxis would be followed the guidance of NHI in&#xD;
      Taiwan, however, the end of our observation would be at week 48 after TAF use. Patients will&#xD;
      receive regular follow up at week 4, 12, 24, 36 and 48 (for T-bil, AST, ALT, creatinine,&#xD;
      HBsAg, HBV DNA) till 1 year and the outcome will be collected. Platelet and HBcrAg would be&#xD;
      examined at enrollment, 24 weeks and 48 weeks. HBeAg and anti-HBeAg will be examined at&#xD;
      enrollment and 48 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 15, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The rate of HBV reactivation during TAF prophylaxis</measure>
    <time_frame>after 48 weeks of TAF use</time_frame>
    <description>Definition of HBV reactivation :&#xD;
HBV DNA increase 2 log (100-fold) compared to the baseline level&#xD;
HBV DNA 3 log (1,000) IU/mL in a patient with previously undetectable level&#xD;
HBV DNA 4 log (10,000) IU/mL if the baseline level is not available</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The dynamic change of eGFR during TAF prophylaxis</measure>
    <time_frame>after 48 weeks of TAF use</time_frame>
    <description>record the dynamic change of eGFR from baseline to 48 weeks after TAF</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Hepatitis B Reactivation</condition>
  <arm_group>
    <arm_group_label>TAF prophylaxis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Using TAF to prevent HBV reactivation for HBsAg-positive cancer patients</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tenofovir alafenamide</intervention_name>
    <description>Tenofovir alafenamide 25 mg once per day for one year</description>
    <arm_group_label>TAF prophylaxis</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult patients (age ≥20) with positive HBsAg who are prepared to receive systemic&#xD;
             chemotherapy&#xD;
&#xD;
          -  The presence of HBs antigen should be confirmed within recent two years&#xD;
&#xD;
          -  The patients who could receive systemic chemotherapy in 4 weeks&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with poor performance status (Zubrod-ECOG ≥ 2 or Karnofsky score ≤ 70)&#xD;
&#xD;
          -  Patients with cirrhosis&#xD;
&#xD;
          -  Patients had eGFR lower than 15 ml/min/1.73m2 and didn't receive dialysis&#xD;
&#xD;
          -  Patients had exposure to any NUC or interferon within 6 months before chemotherapy&#xD;
&#xD;
          -  Patients were co-infected with HCV or HIV&#xD;
&#xD;
          -  Allergy history to any tenofovir-based medication&#xD;
&#xD;
          -  Pregnant woman&#xD;
&#xD;
          -  Unable to sign inform consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Po-Yueh Chen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ditmanson Medical Foundation Chiayi Christian Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Po-Yueh Chen, MD</last_name>
    <phone>+886-5-2765041</phone>
    <phone_ext>5275</phone_ext>
    <email>hdilwy7@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Dalin Tzu Chi General Hospital</name>
      <address>
        <city>Chiayi City</city>
        <zip>600</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kuo-Chi Tseng, MD</last_name>
    </contact>
    <investigator>
      <last_name>Kuo-Chi Tseng, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ditmanson Medical Foundation Chiayi Christian Hospital</name>
      <address>
        <city>Chiayi City</city>
        <zip>600</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Po-Yueh Chen, MD</last_name>
      <phone>+886-5-2765041</phone>
      <phone_ext>5275</phone_ext>
      <email>hdilwy7@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Chi-Yi Chen, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chu-Kuang Chou, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Li-Jen Chang, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Po-Yueh Chen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Martin De Porress Hospital</name>
      <address>
        <city>Chiayi City</city>
        <zip>600</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ching-Chu Lo, MD</last_name>
    </contact>
    <investigator>
      <last_name>Ching-Chu Lo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chi Mei Medical Hospital</name>
      <address>
        <city>Tainan</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jyh-Jou Chen, MD</last_name>
    </contact>
    <investigator>
      <last_name>Jyh-Jou Chen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital, Yun-Lin Branch</name>
      <address>
        <city>Yun-Lin</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yu-Jen Fang, MD</last_name>
    </contact>
    <investigator>
      <last_name>Yu-Jen Fang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 2, 2020</study_first_submitted>
  <study_first_submitted_qc>November 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 6, 2020</study_first_posted>
  <last_update_submitted>June 29, 2021</last_update_submitted>
  <last_update_submitted_qc>June 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>TAF</keyword>
  <keyword>cancer patients</keyword>
  <keyword>chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis B</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenofovir</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

